Note: Descriptions are shown in the official language in which they were submitted.
CA 022~ 1998-10-02
STY-F801/PCT
-- 1 --
DESCRIPTION
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEART DISEASE
- BASED ON CARDIAC HYPERTROPHY
Technical Field
The present invention relates to a pharmaceutical
composition for treatment of heart disease based on
cardiac hypertrophy comprising as its active ingredient a
substance that acts on the natriuretic peptide (NP)
receptor, guanylyl cyclase A (GC-A), and is able to
stimulate production of cyclic guanosine monophosphate
(cGMP).
Background Art
~Following the occurrence of increased load on the
ventricle due to hypertension or valvular heart disease,
or disorders of cardiac myocytes themselves such as
myocardial infarction, myocarditis and cardiomyopathy, the
shape of the ventricle is altered primarily by hypertrophy
of heart muscle cells so as to maintain cardiac output
resulting in the so-called state of cardiac hypertrophy.
Although this cardiac hypertrophy is considered to be an
adaptation phenomenon in response to cardiac myoctes
disorders and mechanical load to a certain extent, when
hypertrophy becomes pronounced due to continuous
application of an excess load, contraction and dilation
functions are hindered. In addition to leading to
decreased cardiac output and chronic heart failure, there
is an increased risk of falling into an ischemic state and
greater susceptibility to potentially fatal arrhythmia.
The degree of cardiac hypertrophy is considered to be one
of the factors that determines the prognosis of heart
disease. According to large-scale progressive surveys as
represented by the Framingham Study, the presence of
cardiac hypertrophy initiates the onset of heart failure,
which in turn has been determined to increase the risk of
angina pectoyis, myocardial infarction and other ischemic
heart diseases as well as arrhythmia by 2.5 to 3 times
CA 022~ 1998-10-02
(Yamazaki, R. and Yazaki, Y., Heart failure, p. 37-45,
Shinoyama, S. ed., Pharmaceutical Journal Publishing,
1997). Thus, a drug that inhibits the excessive formation
of cardiac hypertrophy or reduces the hypertrophy is
considered to be effective in preventing the onset and
progress of heart diseases including chronic heart
failure.
Treatment of chronic heart failure has conventionally
consisted primarily of the use of cardio tonics for the
purpose of improving heart contraction and increasing
cardiac output. However, although cardio tonics exhibit
immediate effects that improve subjective symptoms and
exercise tolerance, they lack effects in terms of
impr~oving survival prognosis, namely a life-extending
effect, which is the ultimate objective of treatment of
chronic heart failure. On the contrary, results have been
obtained indicating that they may actually result in a
worse prognosis (Packer, et al., N. Engl. J. Med., Vol.
325, p. 1468, 1991).
On the other hand, catecholamines, angiotensin II,
aldosterone, endothelin, vasopressin and other
neurohumoral factors have been suggested to be involved in
the occurrence and progress of cardiac hypertrophy, and
development and clinical application has progressed on
drugs that inhibit the production or signal transduction
system of these factors. However, since a plurality of
these factors are involved in the mechanism of occurrence
of cardiac hypertrophy in the body, a drug that exhibits
antagonistic effects on only one of these factors is
expected to be insufficient. For example, although an
inhibitor of angiotensin conversion enzyme (ACE), an
enzyme involved in the production of angiotensin II, has
been observed to inhibit the occurrence and progress of
cardiac hypertrophy in animal models (Brilla, et al.,
Circulation, Vol. 83, p. 1771, 1991), and in the case of
clinical administration to chronic heart failure patients,
extends the prognosis for survival by reducing cardiac
CA 022~ 1998-10-02
hypertrophy (The Save Investigation, N. Engl. J. Med.,
Vol. 327, p. 678, 1992), its effects have as of yet not
been considered to be sufficient.
In actuality, even if the most advanced treatment is
performed, the mortality rate at five years after onset of
chronic heart failure is presently about 50%. Although
endothelin antagonists (Ito, et al., Circulation, Vol. 89,
p. 2198, 1994) and vasopressin antagonists (Tomura, et
al., Circulation, Vol. 94 (Suppl. I-264), 1996) have
recently been reported to inhibit the formation of cardiac
hypertrophy in animal models, there is a need to develop
drugs for the treatment of heart disease that inhibit
cardiac hypertrophy based on a new mechanism.
Disclosure of the Invention
Thus, the object of the present invention is to
provide a pharmaceutical composition effective in
preventing cardiac hypertrophy involved in the onset and
progress of chronic heart failure and other heart
diseases, and more particularly, to provide a
pharmaceutical composition for treatment of heart disease
based on cardiac hypertrophy comprising as its active
ingredient a substance able to stimulate cGMP production
by binding to GC-A, a natriuretic peptide (NP) receptor.
Brief Description of the Drawings
Fig. 1 is a graph showing the time-based changes in
urine excretion volume (A) and urine sodium excretion
amount (B) in a sham group, control group and ANP group in
the case of administering 0.1 ~g/kg/min of ANP or 5%
glucose for 1 week starting immediately after the
operation in a rat model of hypertrophy induced by aortic
banding. ~ indicates the sham group (n = 19), ~ indicates
the control group (n = 20) and ~ indicates the ANP group
(n = 12). In addition, each value represents the mean +
standard error.
Fig. 2 is a graph showing the right atrium
weight/body weight ratio (A), left atrium weight/body
weight ratio (B), right ventricle weight/body weight ratio
~ . .
CA 022~ 1998-10-02
(C) and left ventricle weight/body weight ratio (D) in a
Sham group, control group and ANP group in the case of
administering 0.1 ~g/kg/min of ANP or 5% glucose for 2
weeks starting two weeks after surgery in a rat model of
cardiac hypertrophy induced by arteriovenous shunt of the
abdominal aorta. In addition, * and ** indicate the
presence of a significant difference from the sham group
at p<0.05 and p<0.01, respectively, while # and ##
indicate the presence of a significant difference from the
control group at p<0.05 and p<0.01, respectively. The
results were tested for the presence of a significant
difference by ANOVA analysis.
Fig. 3 is a graph showing the lung weight/body weight
ratio (A) and hematocrit value (B) of a sham group,
control group and ANP group at the end of the study under
the same conditions as in Fig. 2. Each value represents
the mean + standard error of 6 animals. In addition, *
and ** indicate the presence of a significant difference
from the sham group at p<0.05 and p<0.01, respectively,
while # and ## indicate the presence of a significant
difference from the control group at p<0.05 and p<0.01,
respectively. The results were tested for the presence of
a significant difference by ANOVA analysis.
Embodiment for Carrying Out the Invention
The present invention relates to a pharmaceutical
composition for treatment of heart disease based on
cardiac hypertrophy comprising as its active ingredient a
substance that acts on the natriuretic peptide (NP)
receptor, guanylyl cyclase A (GC-A), and is able to
stimulate production of cyclic guanosine monophosphate
(cGMP). Specific examples of heart diseases based on
cardiac hypertrophy include heart failure (e.g., chronic
heart failure), ischemic heart disease (e.g., myocardial
infarction and angina pectoris) and arrhythmia.
There are no particular limitations on substances
that can be used as the active ingredient of the
pharmaceutical composition as claimed by the present
CA 022SllSS 1998-10-02
invention provided that they have the property of being
able to stimulate production of cGMP by way of GC-A, an NP
receptor. Substances having said property can be obtained
(1) in the form of a substance that is able to increase
said activity by measuring intracellular cGMP
concentration, or (2) in the form of a substance that is
able to increase said activity by measuring guanylyl
cyclase activity in cell or tissue membrane fractions that
express GC-A, when the candidate substance is added to
cells or tissue that expresses GC-A (for example, vascular
endothelial cells, vascular smooth muscle cells, adrenal
cortex zona ~lomerular cells, cells in which GC-A is
artificially expressed, or the aorta, pulmonary artery,
glomèrulus and adrenal cortex) followed by incubation.
Furthermore, known methods can be used for the above-
mentioned measurement methods, examples of which are
described in, for example, Min~mitake, Y., et al.,
Biochem. Biophys. Res. Commun., 172, 971-978 (1990),
Furuya, M., et al., Biochem. Biophys. Res. Commun., 177,
927-931 (1991), and Hidaka, Y., et al., Jap. J. Pharm.,
101, 309-325 (1993). Preferable examples of substances
having the above-mentioned property include natriuretic
peptide (NP), more preferably atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP).
Moreover, although human a-hANP consisting of 28
amino acids (Kangawa, et al., Biochem. Biophys. Res.
Commun., Vol. 118, p. 131, 1984) (SEQ ID NO: 1) or rat o~-
rANP (Kangawa, et al., Biochem. Biophys. Res. Commun.,
Vol. 121, p. 585, 1984) (SEQ ID NO: 2) can be used as the
ANP, the peptide of the active ingredient according to the
present invention may be any peptide having an ANP ring
structure (formation of a disulfide bond based on Cys
residues) and a C terminal portions continuing from a ring
structure. An example of said peptide is the peptide
having the amino acid residues at positions 7 through 28
of ~X-hANP (SEQ ID NO: 3). Human (X-hANP is particularly
preferable as the ANP.
CA 022~ 1998-10-02
In addition, an example of BNP is human BNP
consisting of 32 amino acids (Sudoh, et al., Biochem.
Biophys. Res. Commun., Vol. 159, p. 1420, 1989) (SEQ ID
NO: 4).
Based on the amino acid sequence of the above-
mentioned substance (e.g., a-hANP), a person with ordinary
skill in the art could perform modification in the form of
deletion, substitution, addition or insertion on amino
acid residues in said sequence using suitable known
methods, and any of the resulting peptides can be used
provided the resulting peptide acts on the ANP receptor,
- GC-Ai and is able to stimulate production of cGMP.
In addition, peptides that have been isolated and
purified from natural substances, as well as peptides
produced by chemical synthesis or genetic recombination
can also be used as said peptide. In addition to those
previously mentioned, examples of these peptides include
frog ANP (SEQ ID NO: 5), pig NP (SEQ ID NO: 6), rat BNP
(SEQ ID NO: 7) and chicken BNP ( SEQ ID NO: 8).
Moreover, the substance pertaining to the active
ingredient of the pharmaceutical composition of the
present invention can also be used in the form of an acid
addition salt of an inorganic acid such as hydrochloric
acid, sulphonic acid and phosphoric acid, or of an organic
acid such as formic acid, acetic acid, butyric acid,
succinic acid and citric acid. The above-mentioned
substance may also be in the form of a salt resulting from
a metal salt of sodium, potassium, lithium or calcium,
etc., or from an organic base. In addition, the
pharmaceutical composition as claimed in the present
invention may be in the free form of the substance
pertaining to its active ingredient or in the form of its
pharmacologically acceptable salt.
The substance according to the present invention or
its pharmacologically allowable salt is preferably
administered by an administration method typically used
for pharmaceuticals, namely oral administration or non-
... .
CA 022~11S~ 1998-10-02
oral administration such as intravenous administration,
intramuscular administration or subcutaneous
administration, after mixing with a pharmacologically
acceptable carrier, vehicle, diluent or so forth which is
itself known.
In the case the active ingredient is a peptide, since
the peptide is subjected to breakdown in the digestive
organs with oral administration, this administration
method is typically not effective. However, it is also
possible to administer the peptide in the form of a
preparation that is resistant to breakdown in the
digestive organs, for example, a microcapsule preparation
in which the active ingredient in the form of a peptide is
contàined in a ribosome. In addition, peptides can also
be administered by allowing them to be absorbed from a
mucous membrane other than the digestive organs such as
the rectum, within the nose and under the tongue. In this
case, they can be administered in the form of a
suppository, nasal spray or sublingual lozenge.
Although the dose of the pharmaceutical composition
as claimed in the present invention varies according to
the type of disease, patient's age, body weight and
severity of symptoms, and the administration route, it can
typically be administered over a range of 0.1 ~g/kg to 100
mg/kg, and preferably over a range of 0.5 ~g/kg to 5
mg/kg.
ANP is a peptide hormone that is secreted by the
heart and plays an important role in regulating water
electrolyte metabolism and blood pressure. ANP receptors
employ a membrane bonding type of guanylyl cyclase
structure, and are referred to as GC-A or NPR-A. Namely,
ANP bonds to GC-A and increases intracellular levels of
cGMP resulting in physiological effects such as diuresis
and vasodilation.
In humans and model ~nim~1 s, plasma ANP concentration
is known to rise depending on the degree of severity of
cardiac hypertrophy and heart failure. In addition,
.. ..
CA 022~ 1998-10-02
although ANP is primarily synthesized in the atria in the
normal heart, production of ANP in the ventricles
increases remarkably during cardiac hypertrophy. In this
manner, ANP, the production of which is accelerated as the
disease state progresses, is considered to act defensively
in the form of a compensatory mechanism in response to
heart failure. In actuality, vasodilatory and diuretic
effects are exhibited following short-term (1-24 hours)
administration of ANP in acute heart failure patients, and
ANP has been observed to demonstrate effects that relieve
heart preload and afterload, resulted in the improvement
of hemodynamics.
However, whether or not ANP has any effects on
cardiac hypertrophy has yet to be determined. On the
other hand, although Cao, et al. reported that ANP
inhibits DNA synthesis of cultured cardiac fibroblasts in
vitro (Cao, et al., Hypertension, Vol. 25, p. 227, 1995),
the effect of ANP on hypertrophy of cardiac myocytes,
which account for the largest volume in the ventricles
(approx. 70%) and play a central role in cardiac
hypertrophy, has yet to be studied.
Moreover, although diuretic effects and mild
inhibitory effects on cardiac hypertrophy have been
reported to be demonstrated by the inhibition of neutral
endopeptidase (NEP, EC 3.4.24.11), which is involved in
the metabolism and clearance of ANP in the body, in rat
model of cardia hypertrophy volume loading, increases in
blood ANP concentration at this time are not clear. In
addition, since NEP is not only involved in ANP
metabolism, but also in the metabolism of other peptide
hormones such as bradykinin, it is not clear as to whether
diuretic effect and inhibitory effect on cardiac
phypertrophy were actually based on inhibition of
degradation of ANP, namely whether they actually reflected
the effects of ANP (Willenbrock, et al., Hypertension,
Vol. 27, p. 1259, 1996).
In this manner, it cannot be presently determined
CA 022~ 1998-10-02
whether or not the occurrence of cardiac hypertrophy is
inhibited or whether or not cardiac hypertrophy is reduced
by administration of ANP itself.
Thus, the inventors of the present invention examined
the preventive and reducing effects of continuous
administration of ANP on cardiac hypertrophy according to
the method described hereinafter using a model of aradiac
hypertrophy induced by pressure-overload.
In addition, cardiac hypertrophy is induced by
various factors such as increased pressure load due to
high blood pressure and increased volume load due to
valvular heart diseased. Therefore, in order to further
clarify the cardiac hypertrophy inhibitory effects of ANP
on cardiac hypertrophy, in addition to the model of
hypertensive pressure-load described above, another model
of induced by cardiac hypertrophy due to volume-load
abdominal arteriovenous shunt was prepared according to
the method described below. Moreover, since this model
also exhibits pulmonary congestion, a major symptom of
chronic heart failure, the effect of ANP on pulmonary
congestion was also examined.
A. Experimental Method for Investigating Preventive and
Reducing Effects on Cardiac Hypertrophy Using a Model
of Hypertrophy Induced by Pressure-Overload
1. Preparation of Rat Model of Cardiac Hypertrophy
by Pressure Overload
Nine-weeks-old, male Sprague-Dawley rats were
used in the experiment. The animals were anesthetized by
intraperitoneal administration of pentobarbital sodium (40
mg/kg) and then placed in the prone position. Following
laparotomy, the abdominal aorta was exposed and the
portion between the left and right renal arteries was
detached. A 2lG needle was aligned in the aorta and
ligated with silk thread between the left and right renal
arteries together with the aorta. Next, the aorta was
constricted by pulling out the needle. In this model,
systolic blood pressure increases due to constriction of
............ .. .. . .
CA 022SllSS 1998-10-02
-- 10 --
the abdominal aorta in this manner, and this results in
increased cardiac afterload leading to the occurrence of
left ventricle hypertrophy. Only detachment of the
abdominal aorta was performed on animals of a sham
operation (sham) group.
2. ANP A~mi ni stration Method
An incision was made into the necks of rats
under anesthesia induced by intraperitoneal administration
of pentobarbital sodium (40 mg/kg) followed by the
insertion of a silicon catheter into the right jugular
vein. The catheter was lead subcutaneously to cervical
dosal region, and was connected to a microinfusion pump.
Human ANP (a-hANp) was dissolved in 5% glucose and
administered by intravenous infusion at the rate of 0.1
~g/kg/min. 5% glucose was administered by intravenous
infusion at the rate of 2.5 ~l/min to ~nim~l s of the
control and sham groups.
3. Evaluation Method
The rats were anesthetized by intraperitoneal
administration of pentobarbital sodium (40 mg/kg) at the
end of the study followed by the insertion of a
polyethylene catheter into the left carotid artery and
measurement of blood pressure and heart rate by a pressure
transducer. Following measurement, 2 ml of blood was
collected from the carotid artery using a syringe
containing 1/10 volume of 1% (w/v) EDTA 2Na and 5000 KIU/ml
of aprotinin in order to measure plasma a-hANP and rat ANP
concentrations as well as cGMP concentration, a second
messenger of intracellular signal transduction of ANP.
Blood samples were immediately separated by centrifugation
at 4~C, and the resulting plasma was stored at -80~C.
Plasma a-hANP, rat ANP and cGMP were measured by
radioimmunoassay using anti-a-hANP rabbit serum, anti-rat
ANP rabbit serum and anti-succinyl cGMP monoclonal
antibody respectively. Moreover, following blood
sampling, an excess amount of pentobarbital sodium was
administered intravenously to sacrifice the rats. After
.
CA 022~ 1998-10-02
measuring body weight, the hearts of the animals were
- exased and separated into the left ventricle and right
ventricle followed by measurement of their respective
weights. The ratio of left ventricle weight to body
weight was then used as an indicator of cardiac
hypertrophy.
B. Experimental Method for Investigating
Inhibitory Effects on Cardiac Hypertrophy and
Pulmonary Congestion Ameriloration Using a Model of
Cardiac Hypertrophy by Volume Overload
1. Preparation of Rat Model of Cardiac Hypertrophy
by Volume Loading
Nine-weeks-old, male Sprague-Dawley rats were
used in the experiment. The animals were anesthetized by
intraperitoneal administration of pentobarbital sodium (40
mg/kg) and then placed in the prone position. Following
laparotomy, the abdominal aorta and vena cava were exposed
and clamps were placed at the renal artery branch and
femoral artery branch of the aorta to interrupt blood
flow. An 18G needle was inserted into the aorta at the
clamped portions, and advanced into the adjacent interior
vena cava to prepare an arteriovenous shunt. The needle
was withdrawn, the aortic purcuture site was sealed with
surgical adhesive, and the clamps were removed. After
confirming the flow of arterial blood into the vena cava
at the shunt portion, the abdomen was closed. In this
model, venous pressure increased due to the formation of
this abdominal aorta-vena cava shunt resulting in
increased cardiac preload. Loads were applied to the
right atrium, right ventricle, left atrium and left
ventricle in that order leading to the formation of
hypertrophy. Moreover, due to the low compliance of the
venous system, blood began to pool resulting in the
occurrence of pulmonary congestion. Only detachment of
the abdominal aorta and vena cava was performed on animals
of a sham operation (sham) group.
2. ANP Administration Method
CA 022~ 1998-10-02
ANP was administered in the same manner as in
the case of the pressure-loaded cardiac hypertrophy model.
3. Evaluation Method
The rats were anesthetized by intraperitoneal
administration of pentobarbital sodium (40 mg/kg) at
completion of the study followed by the insertion of a
polyethylene catheter into the left carotid artery and
left jugular vein and measurement of blood pressure, heart
rate and right atrial pressure. Following measurement, 2
ml of blood were collected from the carotid artery using a
syringe containing 1/10 volume of 1% (w/v) EDTA 2Na and
5000 KIU/ml of aprotinin in order to measure plasma a-hANP
and rat ANP concentrations. Blood samples were
immediately separated by centrifugation at 4~C, and the
resulting plasma was stored at -80~C. Plasma a-hANP and
rat ANP concentrations were measured by radioimmunoassay
using anti-a-hANP rabbit serum and anti-rat ANP rabbit
serum respectively. In addition, arterial blood was
collected in a hematocrit tube and centrifuged followed by
determination of hematocrit value. Moreover, following
blood sampling, an excess amount of pentobarbital sodium
was administered intravenously to sacrifice the rats.
After measuring body weight, the hearts of the animals
were excised and separated into the right atrium, left
atrium, right ventricle, left ventricle and lungs followed
by measurement of their respective weights. The ratios of
each heart chamber and lungs to body weight was then used
as an indicator of cardiac hypertrophy and pulmonary
congestion.
Examples
The following provides a detailed explanation of the
present invention through Examples.
Exam~le 1. StudY of the Preventive Effects of ANP on
Cardiac Hv~ertro~hy
The inventors of the present invention first examined
the cardiac hypertrophy preventive effects of ANP. A
silicon catheter was inserted into the jugular vein
CA 022Sll~ l998-l0-02
- 13 -
immediately after performing abdominal aorta constriction
surgery or sham surgery on rats, followed by continuous
intravenous infusion of ~-hANP at 0.1 ~g/kg/min or 5%
glucose at 2.5 ~l/min for 1 week. One week later,
hemodynamic parameters of the rats were measured under
anesthesia, and the weight of the heart was measured after
sacrificing the animals following collection of blood
samples. Those results are shown in Table 1.
Table 1: Effects of Continuous Intravenous Infusion of ANP~0 for 1 Week on Body Weight, Heart Weight, Blood Pressure
and Heart Rate in Rats with Aortic-Banding
Group No. of Body Systol- Heart Left Left Right Right
animals weight ic rate ventri- ventri- ventri- ventri-
(g) press- (beats/ cle cle cle cle
ure min) weight weight/ weight weight/
(mmHg) (mg) body (mg) body
weight weight
(mg/g) (mg/5)
Sham l9 282+2 146+3 450+7565+102.01+ 154+3 0.54+
0.03 0.01
Control 20 269+4 188+5** 470+10 628+ 2.34+ 149+4 0.56+
12** 0.07** 0.02
ANP 12 283+3 188+8** 465+7 592+102.09+ 147+4 0.52+
0.04# 0.02
Sham surgery was performed on animals of the sham
group, while abdominal aorta constriction surgery was
performed on animals of the control and ANP groups.
Continuous intravenous infusion of 5% glucose at 2.5
~l/min for animals of the sham and control groups, or a-
hANP at 0.1 ~g/kg/min for animals of the ANP group, was
performed for 1 week starting immediately after surgery.
Each value represents the mean + standard error.
Single and double asterisks (*, **) indicate the
presence of a significant difference with the sham group
at p<0.05 or p<0.01, respectively, as determined by one-
way analysis of variance (ANOVA).
Number marks (#) indicate the presence of a
significant difference with the control group at p<0.05 as
determined by ANOVA analysis.
As shown in Table 1, there were no significant
differences observed in body weight and heart rate among
CA 022~ l998-l0-02
- 14 -
the sham, control and ANP groups one week after aortic
banding and the start of drug administration. In the
control group, a significant increase in systolic blood
pressure as compared with the sham group was observed due
5 to increased vascular resistance resulting from aortic
banding, and ANP did not affect blood pressure. On the
other hand, although a significant increase in left
ventricle weight as compared with the sham group was
observed in the control group, increasing significantly
from 2.01+0.03 to 2.34+0.07, in the ANP group, there was
little increase in left ventricle weight, while the ratio
of left ventricle weight to body weight (mg/g) was
significantly less than the control group at 2.09+0.04.
There were no differences in the ratio of right ventricle
15 weight/body weight among any of the groups.
Plasma a-hANP concentration on day 7 of
administration in the ANP group was 502+72 pg/ml (approx.
0.17 nM). In addition, the plasma concentration of cGMP,
a second messenger of intracellular signal transduction of
20 ANP, was 5.3+0.4 pmole/ml in the ANP group, thus
indicating higher values than those of the sham and
control groups ( 2.0+0.3 and 3.4+0.5 pmole/ml,
respectively), thereby confirming that ANP was infused
continuously.
In addition, in contrast to intrinsic ANP
concentration in plasma being 83+8 pg/ml in the sham
group, it significantly increased to 139+19 pg/ml in the
control group. This suggests that compensatory secretion
of intrinsic ANP was increased in response to heart load
induced by aortic banding.
On the other hand, intrinsic ANP concentration in the
ANP group tended to exhibit a low value of 113+10 pg/ml in
reflection of inhibition of the formation of hypertrophy.
In addition, in this study, the rats were housed in
35 metabolic cages after the start of a-hANP administration
and urine was collected every 24 hours to measure urine
volume and urine sodium excretion. As shown in Fig. 1,
CA 022~ 1998-10-02
there were no significant differences observed in urine
volume or urine sodium excretion during the administration
period among any of the groups, and diuretic effects
produced by administration of ANP were not observed in
this model.
In this manner, the formation of cardiac hypertrophy
was shown to be inhibited by continuous intravenous
infusion of ANP for 1 week. At this time, since there
were no effects on body weight or right ventricle weight,
the effect of ANP was considered to be specific for the
left ventricle which is subjected to loading, and not the
result of systemic metabolic disturbances or cytotoxicity.
In addition, since diuretic and hypotensive effects of ANP
werè not observed in this model at the dose level (0.1
~g/kg/min) used in this study, ANP is suggested to have
inhibited the onset of cardiac hypertrophy by acting
directly on the heart.
Example 2. StudY of Reducinq Effects of ANP on
Cardiac Hvpertrophy
Next, the potential for having reducing effects on
cardiac hypertrophy was examined by continuously infusion
of ANP after hypertrophy had already occurred according to
the protocol indicated in Embodiment 1.
After cardiac hypertrophy had reached a steady state
by allowing rats on which abdominal aortic banding or sham
surgery had been performed to go untreated for 15 weeks, a
silicon catheter was inserted into the jugular vein
followed by continuous intravenous infusion of a-hANP at
0.1 ~g/kg/min or 5% glucose at 2.5 ~l/min for 3 weeks.
Hemodynamics of the rats were measured under anesthesia 3
weeks after the start of administration, and the rats were
sacrificed after collecting blood samples followed by
measurement of heart weight. Measured values for heart
weight and hemodynamics parameters at the end of drug
administration in the sham, control and ANP groups are
shown in Table 2.
CA 022~llS~ l998-l0-02
- 16 -
Table 2: Effects of Continuous Intravenous Infusion of ANP
for 3 Weeks on Body Weight, Heart Weight, Blood Pressure
and Heart Rate in Rats 15 Weeks After Abdominal Aortic-
Banding
Group No. of Body Systol- Heart Left Left Right Right
animals weight ic rate ventri- ventri- ventri- ventri-
(g) press- (beats/ cle cle cle cle
ure min) weight weight/ weight weight/
(mmHg) (mg) body (mg)body
weight weight
(mg/g) (mg/g)
Sham 9 523+11 136+8380+16 938+151.80+ 217+6 0.42+
0-04 0.02
Control 9 492+10 214+8** 428+1171+ 2.38+ 214+6 0.44+
14**25**0.05*~ 0.01
ANP 12 502+9 205+8** 451i9**1056+2.11+ 220+4 0.44+
20**,## 0.06**, 0.01
##
Sham surgery was performed on animals of the sham
group, while abdominal aortic banding was performed on
~n i mal S of the control and ANP groups. Continuous
intravenous infusion of 5% glucose at 2.5 ~l/min for
animals of the sham and control groups, or a-hANP at 0.1
~g/kg/min for animals of the ANP group, was performed for
3 weeks starting 15 weeks after surgery.
Each value represents the mean ~ standard error.
Single and double asterisks (*, **) indicate the
presence of a significant difference with the sham group
at p<0.05 or p<0.01, respectively, as determined by one-
way analysis of variance (ANOVA).
Number marks (##) indicate the presence of a
significant difference with the control group at p<0.01 as
determined by one-way analysis of variance (ANOVA).
As is shown in Table 2, there were no significant
differences in body weight among the groups. In the
control group, a significant increase in systolic blood
pressure as compared with the sham group was observed due
to increased vascular resistance resulting from aortic
banding, and effects of ANP on blood pressure were not
observed. Heart rate was significantly increased in the
control and ANP groups as compared with the sham group.
. . .
CA 022~ 1998-10-02
Left ventricle weight and the ratio of left ventricle
weight/body weight used as an indicator of cardiac
hypertrophy were significantly increased in the control
group (2.36+0.05) and ANP group (2.11+0.06) as compared
with the sham group (1.80+0.04), and although cardiac
hypertrophy was observed, significantly lower values were
exhibited by the ANP group as compared with the control
group, thus indicating a reduction in hypertrophy. There
were no differences in the ratio of right ventricle
weight/body weight in any of the groups, thus indicating
that the heart weight lowering effect of ANP was specific
for the hypertrophied left ventricle.
Furthermore, since the left ventricle weight 15 weeks
after surgery when drug administration was started was
937+23 mg in the sham group and 1199+28 mg in the control
group (n = 3 for each), there was a prominent increase in
left ventricle weight in the control group as compared
with the sham group, thus indicating the formation of
cardiac hypertrophy. Since there were no differences in
heart weight at this time between that at completion of
drug administration (after 18 weeks) [sham group: 938+15
mg; control group: 1171+25 mg (n = 9 for each)], this
indicated that cardiac hypertrophy due to pressure loading
had been completed and reached a steady state by 15 weeks
after surgery, and that there was very little additional
progress of hypertrophy during the drug administration
period (15 to 18 weeks after surgery). Thus, the fact
that the ratio of left ventricle weight/body weight
decreased by the administration of ANP starting 15 weeks
after surgery suggests that ANP is effective for the
reduction of hypertrophy that has already formed.
At this time, intrinsic rat ANP concentration was
significantly increased in the control group (126+9 pg/ml)
as compared with the sham group (70+5 pg/ml), and tended
to be lower (105+18 pg/ml) in the ANP group. In addition,
plasma a-hANP concentration at completion of
administration in the ANP group was 426+53 pg/ml (approx.
CA 022~ l998-l0-02
- 18 -
0.14 nM).
In this manner, ANP demonstrated effects that not
only prevent the formation of cardiac hypertrophy, but
also cause a reduction in hypertrophy that has already
formed.
Example 3. Studv of Cardiac hY~ertrophy and
Pulmonarv Conqestion Alleviatinq Effects of ANP
Continuous intravenous infusion of a-hANP at 0.1
~g/kg/min or 5% glucose at 2.5 ~l/min was performed in
rats starting 2 weeks after performing arteriovenous shunt
surgery or sham surgery to examine the effects of ANP on
cardiac hypertrophy and pulmonary congestion. Measured
values for body weight and hemodynamics parameters at the
end of drug administration in the sham, control and ANP
groups are shown in Table 3.
Table 3: Effects of Continuous Intravenous Infusion of ANP
for 2 Weeks on Body Weight, Blood Pressure, Heart Rate and
Right Atrial Pressure in Rats 2 Weeks After Arteriovenous
Shunt Surgery
Group No. of Body weight Systolic Heart rateRight
animals(g) pressure (beats/min) atrial
(mmHg) pressure
( mmHg )
Sham 6 375+10 148=7 4 4=21 7.3+0.5
Control 6 373+12 145=6 4:6=1813.6+2.6**
ANP 6 369+9 143=4 460=1412.6+0.7*
Sham surgery was performed on animals of the sham
group, while abdominal arteriovenous shunt surgery was
performed on animals of the control and ANP groups.
Continuous intravenous infusion of 5% glucose at 2.5
~l/min for animals of the sham and control groups, or ~-
hANP at 0.1 ~g/kg/min for animals of the ANP group, was
performed for 2 weeks starting 2 weeks after surgery.
Each value represents the mean + standard error.
Single and double asterisks (*, **) indicate the
presence of a significant difference with the sham group
at p<0.05 or p<0.01, respectively, as determined by ANOVA
analysis.
As shown in Table 3, there were no significant
CA 022SllSS 1998-10-02
-- 19 --
differences in body weight among any of the groups. There
were also no differences in mean blood pressure and heart
rate among the groups. In the control group, a
significant increase in right atrial pressure was observed
in comparison with the sham group due to increased volume
loading induced by arteriovenous shunt. Right atrial
pressure was also increased in the ANP group similar to
the control group, and effects of ANP on hemodynamics were
not observed.
In addition, the ratios (mg/g) of right atrium, left
atrium, right ventricle and left ventricle weights to body
weight, which served as indicators of cardiac hypertrophy,
are shown in Fig. 2. Values were significantly higher in
the control group as compared with the sham group at all
sites, thus indicating prominent formation of hypertrophy.
On the other hand, the ratios of right atrium, left
atrium, right ventricle and left ventricle weights to body
weight were all significantly lower in the ANP group as
compared with the control group, thereby indicating that
ANP inhibited the formation of cardiac hypertrophy.
Moreover, the ratio of lung weight to body weight
(mg/g) and hematocrit (%), which served as indicators of
pulmonary congestion, are shown in Fig. 3. Although the
control group exhibited significantly higher values than
the sham group with respect to the ratio of lung weight to
body weight [sham group: 4.02+0.13; control group:
4.81+0.17], in the ANP group, values decreased to about
the same level as the sham group (4.06+0.25), with ANP
observed to ameliorate pulmonary congestion. With respect
to hematocrit values as well, since the control group
exhibited lower values than the sham group, increased
blood volume, namely a trend towards systemic congestion,
was suggested, while values in the ANP group were
improved.
Since ANP did not affect blood pressure or right
atrial pressure in this model as well at the dose levels
used in this study (0.1 ~g/kg/min), ANP is believed to
.. . ... . .
CA 022~ l998-l0-02
- 20 -
have inhibited the onset of hypertrophy by acting directly
- on the heart. In contrast to intrinsic rat ANP
concentration at this time having been 43+11 pg/ml in the
sham group, it increased remarkably to 854+265 pg/ml in
the control group, while decreasing significantly in the
ANP group ( 419+202 pg/ml). These results support the
results of cardiac hypertrophy formation by shunt surgery
as well as inhibition of cardiac hypertrophy by
administration of ANP. In addition, the plasma a-hANp
concentration at completion of administration in the ANP
group was 329+113 pg/ml (approx. 0.11 nM).
Furthermore, although a slight increase in the ratio
of right atrium weight to body weight was observed in the
control group as compared with the sham group at 2 weeks
15 after surgery when drug administration was started (sham
group: 0.10+0.01 (n = 6), control group: O.13+0.004 (n =
8)), there were no differences between the groups with
respect to the ratios of left atrium, right ventricle,
left ventricle and lung weights to body weight, while
20 plasma rat ANP concentration only tended to be slightly
increased (sham group: 34+3 pg/ml (n = 6), control group:
47+8 pg/ml (n = 8) ) . In this manner, there was hardly any
occurrence of a disease state at 2 weeks after abd~mi n~l
aorta arteriovenous shunt surgery, while the disease state
25 iS believed to have progressed from 2 weeks to 4 weeks
after surgery. Thus, it was suggested that administration
of ANP from 2 weeks to 4 weeks after surgery inhibited the
formation of cardiac hypertrophy and pulmonary congestion.
As has been described above, ANP was shown to inhibit
30 not only hypertensive left ventricular hypertrophy induced
by pressure loading, but also the formation of cardiac
hypertrophy induced by volume loading. In addition, ANP
was also shown to be effective not only in terms of the
onset of cardiac hypertrophy, but also in terms of
35 ameliorating pulmonary congestion.
Industrial Applicability
The present invention has proven that a composition
CA 022~ l998-l0-02
- 21 -
having for its active ingredient a substance that acts on
the natriuretic peptide receptor, GC-A, and is able to
stimulate production of cGMP is effective in preventing
cardiac hypertrophy involved in the onset and progress of
heart diseases such as chronic heart failure. In the case
of using ANP as the active ingredient in particular, the
fact that ANP not only inhibited the formation of
hypertrophy but also exhibited reducing effects in a
pressure-loaded hypertrophy model suggests that it is
therapeutically effective and clinically useful in the
case of using in patients in which cardiac hypertrophy has
already occurred.
In addition, since ANP exhibited inhibitory effects
on cardiac hypertrophy as well as pulmonary congestion
ameliorating effects in a volume-loaded hypertrophy model,
it was suggested that ANP is also effective in the case of
using in patients with pulmonary congestion, a major
symptom of chronic heart failure and a cause of dyspnea.
Moreover, since ANP exhibits inhibitory effects on
hypertrophy and pulmonary congestion at dose levels at
which it does not affect blood pressure, heart rate or
urine volume, it has few adverse side effects in terms of
hemodynamics and is considered to be able to be used
safely.
Based on these results, ANP was strongly suggested to
be able to improve cardiac hypertrophy based on high blood
pressure, valvopathy or myocardial infarction, as well as
pulmonary congestion that occurs as a result of cardiac
dysfunction. Cardiac hypertrophy is itself an independent
risk factor for ischemic heart disease, arrhythmia and
chronic heart failure, while chronic heart failure in
particular is a disease having a high mortality rate and
poor prognosis. Accordingly, under the present
circumstances in which there is an extremely dire need for
a new drug that is effective in improving cardiac
hypertrophy and ameliorating the load on the heart, the
pharmaceutical composition for treatment of heart disease
CA 02251155 1998-10-02
-- 22 --
based on cardiac hypertrophy as claimed in the present
invention is extremely useful.
CA 022~ l998-l0-02
SEQUENCE LISTING
Sequence No.: 1
Sequence length: 28
Sequence type: Amino acid
Topology: Linear
Molecular type: Peptide
Sequence
Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly
5 10 15
Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
Sequence No.: 2
Sequence length: 28
Sequènce type: Amino acid
Topology: Linear
Molecular type: Peptide
Sequence
Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly
5 10 15
Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
Sequence No.: 3
Sequence length: 22
Sequence type: Amino acid
Topology: Linear
Molecular type: Peptide
Sequence
Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly
Cys Asn Ser Phe Arg Tyr
Sequence No.: 4
Sequence length: 32
Sequence type: Amino acid
Topology: Linear
Molecular type: Peptide
Sequence
CA 022~ l998-l0-02
Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp
S 10 15
Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His
Sequence No.: 5
Sequence length: 24
Sequence type: Amino acid
Topology: Linear
Molecular type: Peptide
Sequence
Ser Ser Asp Cys Phe Gly Ser Arg Ile Asp Arg Ile Gly Ala Gln Ser
Gly Met Gly Cys Gly Arg Arg Phe
Sequence No.: 6
Sequence length: 32
Sequence type: Amino acid
Topology: Linear
Molecular type: Peptide
Sequence
Ser Pro Lys Thr Met Arg Asp Ser Gly Cys Phe Gly Arg Arg Leu Asp
Arg Ile Gly Ser Leu Ser Gly Leu Gly Cys Asn Val Leu Arg Arg Tyr
Sequence No.: 7
Sequence length: 45
Sequence type:
No. of chains:
Topology: Linear
Molecular type:
Sequence
Ser Gln Asp Ser Ala Phe Arg Ile Gln Glu Arg Leu Arg Asn Ser Lys
Met Ala His Ser Ser Ser Cys Phe Gly Gln Lys Ile Asp Arg Ile Gly
Ala Val Ser Arg Leu Gly Cys Asp Gly Leu Arg Leu Phe
CA 02251155 1998-10-02
- 25 -
Sequence No.: 8
Sequence length: 29
Sequence type: Amino acid
Topology: Linear
Molecular type: Peptide
Sequence
Met Met Arg Asp Ser Gly Cys Phe Gly Arg Arg Ile Asp Arg Ile Gly
1 5 10 15
Ser Leu Ser Gly Met Gly Cys Asn Gly Ser Arg Lys Asn
.
